Suzhou Wangshan Wangshui Biopharmaceutical

Suzhou Wangshan Wangshui Biopharmaceutical is a Chinese clinical-stage biotechnology company specializing in the discovery and development of innovative small molecule drugs. The company maintains a strong focus on anti-infective therapies, particularly for viral diseases such as COVID-19, HIV, and Hepatitis B, as well as treatments for central nervous system (CNS) disorders. Its most notable achievement is the development of VV116 (Mindevir), an oral nucleoside analog for COVID-19, which was developed in collaboration with Junshi Biosciences and the Shanghai Institute of Materia Medica. Wangshan Wangshui leverages deep academic ties with the Chinese Academy of Sciences to advance a pipeline that includes both novel chemical entities and high-barrier generic drugs. The company is headquartered in the Suzhou Industrial Park and operates integrated R&D and pilot production facilities.